Advertisement

Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression

Published:September 19, 2008DOI:https://doi.org/10.1016/j.biopsych.2008.08.010

      Background

      Interferon (IFN)-alpha has been used to study the effects of innate immune cytokines on the brain and behavior in humans. The degree to which peripheral administration of IFN-alpha accesses the brain and is associated with a central nervous system (CNS) inflammatory response is unknown. Moreover, the relationship among IFN-alpha-associated CNS inflammatory responses, neurotransmitter metabolism, and behavior has yet to be established.

      Methods

      Twenty-four patients with hepatitis C underwent lumbar puncture and blood sampling after ∼12 weeks of either no treatment (n = 12) or treatment with pegylated IFN-alpha 2b (n = 12). Cerebrospinal fluid (CSF) and blood samples were analyzed for proinflammatory cytokines and their receptors as well as the chemokine, monocyte chemoattractant protein-1 (MCP-1), and IFN-alpha. Cerebrospinal fluid samples were additionally analyzed for monoamine metabolites and corticotropin releasing hormone. Depressive symptoms were assessed using the Montgomery Asberg Depression Rating Scale.

      Results

      Interferon-alpha was detected in the CSF of all IFN-alpha-treated patients and only one control subject. Despite no increases in plasma IL-6, IFN-alpha-treated patients exhibited significant elevations in CSF IL-6 and MCP-1, both of which were highly correlated with CSF IFN-alpha concentrations. Of the immunologic and neurotransmitter variables, log-transformed CSF concentrations of the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were the strongest predictor of depressive symptoms. Log-transformed CSF concentrations of IL-6, but not IFN-alpha or MCP-1, were negatively correlated with log-transformed CSF 5-HIAA (r2 = −.25, p < .05).

      Conclusions

      These data indicate that a peripherally administered cytokine can activate a CNS inflammatory response in humans that interacts with monoamine (serotonin) metabolism, which is associated with depression.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Raison C.L.
        • Capuron L.
        • Miller A.H.
        Cytokines sing the blues: Inflammation and the pathogenesis of major depression.
        Trends Immunol. 2006; 27: 24-31
        • Dantzer R.
        • O'Connor J.C.
        • Freund G.G.
        • Johnson R.W.
        • Kelley K.W.
        From inflammation to sickness and depression: When the immune system subjugates the brain.
        Nat Rev Neurosci. 2008; 9: 46-56
        • Yirmiya R.
        • Weidenfeld J.
        • Pollak Y.
        • Morag M.
        • Morag A.
        • Avitsur R.
        • et al.
        Cytokines, “depression due to a general medical condition,” and antidepressant drugs.
        Adv Exp Med Biol. 1999; 461: 283-316
        • Abbas A.K.
        • Lichtman A.H.
        Cellular and Molecular Immunology, 5th ed.
        W.B. Saunders Company, Philadelphia2003
        • Quan N.
        • Banks W.A.
        Brain-immune communication pathways.
        Brain Behav Immun. 2007; 21: 727-735
        • Ericsson A.
        • Kovacs K.J.
        • Sawchenko P.E.
        A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons.
        J Neurosci. 1994; 14: 897-913
        • Goehler L.E.
        • Gaykema R.P.
        • Hansen M.K.
        • Anderson K.
        • Maier S.F.
        • Watkins L.R.
        Vagal immune-to-brain communication: A visceral chemosensory pathway.
        Auton Neurosci. 2000; 85: 49-59
        • Kirkwood J.
        Cancer immunotherapy: The interferon-alpha experience.
        Semin Oncol. 2002; 29: 18-26
        • Dorr R.T.
        Interferon-alpha in malignant and viral diseases.
        Drugs. 1993; 45: 177-211
        • Musselman D.L.
        • Lawson D.H.
        • Gumnick J.F.
        • Manatunga A.K.
        • Penna S.
        • Goodkin R.S.
        • et al.
        Paroxetine for the prevention of depression induced by high-dose interferon alfa [see comments].
        N Engl J Med. 2001; 344: 961-966
        • Schaefer M.
        • Engelbrecht M.A.
        • Gut O.
        • Fiebich B.L.
        • Bauer J.
        • Schmidt F.
        • et al.
        Interferon alpha (IFNa) and psychiatric syndromes: A review.
        Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26: 731-746
        • Raison C.L.
        • Demetrashvili M.
        • Capuron L.
        • Miller A.H.
        Neuropsychiatric side effects of interferon-alpha: Recognition and management.
        CNS Drugs. 2005; 19: 1-19
        • Lotrich F.E.
        • Rabinovitz M.
        • Gironda P.
        • Pollock B.G.
        Depression following pegylated interferon-alpha: Characteristics and vulnerability.
        J Psychosom Res. 2007; 63: 131-135
        • Asnis G.M.
        • De La Garza 2nd, R.
        Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches [see comment].
        J Clin Gastroenterol. 2006; 40: 322-335
        • Orru M.G.
        • Baita A.
        • Sitzia R.
        • Costa A.
        • Muntoni E.
        • Landau S.
        • et al.
        [Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: A prospective, observational, controlled study].
        Epidemiol Psychiatr Soc. 2005; 14: 145-153
        • Wichers M.C.
        • Kenis G.
        • Koek G.H.
        • Robaeys G.
        • Nicolson N.A.
        • Maes M.
        Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.
        J Psychosom Res. 2007; 62: 207-214
        • Bonaccorso S.
        • Marino V.
        • Puzella A.
        • Pasquini M.
        • Biondi M.
        • Artini M.
        • et al.
        Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
        J Clin Psychopharmacol. 2002; 22: 86-90
        • Capuron L.
        • Ravaud A.
        • Neveu P.J.
        • Miller A.H.
        • Maes M.
        • Dantzer R.
        Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.
        Mol Psychiatry. 2002; 7: 468-473
        • Schaefer M.
        • Schwaiger M.
        • Pich M.
        • Lieb K.
        • Heinz A.
        Neurotransmitter changes by interferon-alpha and therapeutic implications.
        Pharmacopsychiatry. 2003; 36: S203-S206
        • Raison C.L.
        • Borisov A.S.
        • Woolwine B.J.
        • Massung B.
        • Vogt G.
        • Miller A.H.
        Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: Relationship with proinflammatory cytokines and behavior [published online ahead of print June 3].
        Mol Psychiatry. 2008;
        • Capuron L.
        • Raison C.L.
        • Musselman D.L.
        • Lawson D.H.
        • Nemeroff C.B.
        • Miller A.H.
        Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
        Am J Psychiatry. 2003; 160: 1342-1345
        • Taylor J.L.
        • Grossberg S.E.
        The effects of interferon-alpha on the production and action of other cytokines.
        Semin Oncol. 1998; 25: 23-29
        • Wichers M.C.
        • Kenis G.
        • Leue C.
        • Koek G.
        • Robaeys G.
        • Maes M.
        Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment.
        Biol Psychiatry. 2006; 60: 77-79
        • Friebe A.
        • Schwarz M.J.
        • Schmid-Wendtner M.
        • Volkenandt M.
        • Schmidt F.
        • Horn M.
        • et al.
        Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
        J Immunother. 2007; 30: 333-337
        • Monteiro de Almeida S.
        • Letendre S.
        • Zimmerman J.
        • Lazzaretto D.
        • McCutchan A.
        • Ellis R.
        Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma.
        J Neuroimmunol. 2005; 169: 144-152
        • Chang L.
        • Ernst T.
        • St Hillaire C.
        • Conant K.
        Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.
        Antivir Ther. 2004; 9: 431-440
        • Cinque P.
        • Vago L.
        • Mengozzi M.
        • Torri V.
        • Ceresa D.
        • Vicenzi E.
        • et al.
        Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication.
        AIDS. 1998; 12: 1327-1332
        • Rho M.B.
        • Wesselingh S.
        • Glass J.D.
        • McArthur J.C.
        • Choi S.
        • Griffin J.
        • et al.
        A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia.
        Brain Behav Immun. 1995; 9: 366-377
        • Krivine A.
        • Force G.
        • Servan J.
        • Cabee A.
        • Rozenberg F.
        • Dighiero L.
        • et al.
        Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: Insights into the pathogenesis of AIDS Dementia Complex.
        J Neurovirol. 1999; 5: 500-506
        • Hokeness K.L.
        • Kuziel W.A.
        • Biron C.A.
        • Salazar-Mather T.P.
        Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver.
        J Immunol. 2005; 174: 1549-1556
        • Rankine E.L.
        • Hughes P.M.
        • Botham M.S.
        • Perry V.H.
        • Felton L.M.
        Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment.
        Eur J Neurosci. 2006; 24: 77-86
        • Mendels J.
        • Frazer A.
        • Fitzgerald R.G.
        • Ramsey T.A.
        • Stokes J.W.
        Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients.
        Science. 1972; 175: 1380-1382
        • Mendels J.
        • Frazer A.
        Brain biogenic amine depletion and mood.
        Arch Gen Psychiatry. 1974; 30: 447-451
        • Szabo S.T.
        • Gould T.D.
        • Manji H.K.
        Neurotransmitters, receptors, signal transduction, and second messengers in psychiatric disorders.
        in: Schatzberg A.F. Nemeroff C.B. Textbook of Psychopharmacology. American Psychiatric Publishing, Washington, DC2004: 3-52
        • First M.B.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.
        Structured Clinical Interview for DSM-IV.
        American Psychiatric Press, Washington DC1997
        • Folstein M.F.
        • Folstein S.E.
        • McHugh P.R.
        “Mini-mental state”.
        J Psychiatr Res. 1975; 12: 189-198
        • Majer M.
        • Wellberg L.A.M.
        • Capuron L.
        • Pagnoni G.
        • Raison C.L.
        • Miller A.H.
        IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.
        Brain Behav Immun. 2008; 22: 870-880
        • Montgomery S.A.
        • Asberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Wightman R.M.
        • Plotsky P.M.
        • Strope E.
        • Delcore Jr, R.
        • Adams R.N.
        Liquid chromatographic monitoring of CSF metabolites.
        Brain Res. 1977; 131: 345-349
        • Felger J.C.
        • Alagbe O.
        • Hu F.
        • Mook D.
        • Freeman A.A.
        • Sanchez M.M.
        • et al.
        Effects of interferon-alpha on rhesus monkeys: A non-human primate model of cytokine-induced depression.
        Biol Psychiatry. 2007; 62: 1324-1333
        • Collins J.M.
        • Riccardi R.
        • Trown P.
        • O'Neill D.
        • Poplack D.G.
        Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: Comparison of intravenous, intramuscular, and intraventricular delivery.
        Cancer Drug Deliv. 1985; 2: 247-253
        • Wang J.
        • Campbell I.L.
        • Zhang H.
        Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system.
        Mol Psychiatry. 2008; 13: 293-301
        • Pan W.
        • Banks W.A.
        • Kastin A.J.
        Permeability of the blood-brain and blood-spinal cord barriers to interferons.
        J Neuroimmunol. 1997; 76: 105-111
        • Indraccolo S.
        • Pfeffer U.
        • Minuzzo S.
        • Esposito G.
        • Roni V.
        • Mandruzzato S.
        • et al.
        Identification of genes selectively regulated by IFNs in endothelial cells.
        J Immunol. 2007; 178: 1122-1135
        • Tissari J.
        • Siren J.
        • Meri S.
        • Julkunen I.
        • Matikainen S.
        IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression.
        J Immunol. 2005; 174: 4289-4294
        • Honda K.
        • Yanai H.
        • Negishi H.
        • Asagiri M.
        • Sato M.
        • Mizutani T.
        • et al.
        IRF-7 is the master regulator of type-I interferon-dependent immune responses.
        Nature. 2005; 434: 772-777
        • Shehata M.
        • Schwarzmeier J.D.
        • Nguyen S.T.
        • Hilgarth M.
        • Berger R.
        • Hubmann R.
        • et al.
        Reconstitution of endogenous interferon a by recombinant interferon in hairy cell leukemia.
        Cancer Res. 2000; 60: 5420-5426
        • Stamatovic S.M.
        • Shakui P.
        • Keep R.F.
        • Moore B.B.
        • Kunkel S.L.
        • Van Rooijen N.
        • et al.
        Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability.
        J Cereb Blood Flow Metab. 2005; 25: 593-606
        • McManus C.M.
        • Liu J.S.
        • Hahn M.T.
        • Hua L.L.
        • Brosnan C.F.
        • Berman J.W.
        • et al.
        Differential induction of chemokines in human microglia by type I and II interferons.
        Glia. 2000; 29: 273-280
        • Yamada T.
        • Yamanaka I.
        Microglial localization of alpha-interferon receptor in human brain tissues.
        Neurosci Lett. 1995; 189: 73-76
        • Barth P.G.
        The neuropathology of Alcardi-Goutieres syndrome.
        Eur J Paediatr Neurol. 2002; 6: A27-A31
        • Shiozawa S.
        • Kuroki Y.
        • Kim M.
        • Hirohata S.
        • Ogino T.
        Interferon-alpha in lupus psychosis.
        Arthritis Rheum. 1992; 35: 417-422
        • Jonsen A.
        • Bengtsson A.A.
        • Nived O.
        • Ryberg B.
        • Truedsson L.
        • Ronnblom L.
        • et al.
        The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles.
        Lupus. 2003; 12: 846-850
        • Abbott R.J.
        • Bolderson I.
        • Gruer P.J.
        Assessment of an immunoassay for interferon-alpha in cerebrospinal fluid as a diagnostic aid in infections of the central nervous system.
        J Infect. 1987; 15: 153-160
        • Ichimura H.
        • Shimase K.
        • Tamura I.
        • Kaneto E.
        • Kurimura O.
        • Aramitsu Y.
        • et al.
        Neutralizing antibody and interferon-alpha in cerebrospinal fluids and sera of acute aseptic meningitis.
        J Med Virol. 1985; 15: 231-237
        • Raison C.L.
        • Woolwine B.J.
        • Binongo J.
        • Staub J.
        • Weinrieb R.M.
        • Rosenblate R.
        • et al.
        Paroxetine for the prevention of depression in patients undergoing treatment with interferon-alpha plus ribavirin for hepatitis C.
        Brain Behav Immun. 2006; 20: E58
        • Schaefer M.
        • Schwaiger M.
        • Garkisch A.S.
        • Pich M.
        • Hinzpeter A.
        • Uebelhack R.
        • et al.
        Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C [see comment].
        J Hepatol. 2005; 42: 793-798
        • Hauser P.
        • Khosla J.
        • Aurora H.
        • Laurin J.
        • Kling M.A.
        • Hill J.
        • et al.
        A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.
        Mol Psychiatry. 2002; 7: 942-947
        • Kraus M.R.
        • Schafer A.
        • Faller H.
        • Csef H.
        • Scheurlen M.
        Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.
        Aliment Pharmacol Ther. 2002; 16: 1091-1099
        • Bull S.J.
        • Huezo-Diaz P.
        • Binder E.B.
        • Cubells J.F.
        • Ranjith G.
        • Maddock C.
        • et al.
        Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment [published online ahead of print May 6].
        Mol Psychiatry. 2008;
        • Zhu C.B.
        • Blakely R.D.
        • Hewlett W.A.
        The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters.
        Neuropsychopharmacology. 2006; 31: 2121-2131
        • Zhu C.B.
        • Carneiro A.M.
        • Dostmann W.R.
        • Hewlett W.A.
        • Blakely R.D.
        p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process.
        J Biol Chem. 2005; 280: 15649-15658
        • Sanchez M.M.
        • Alagbe O.
        • Felger J.C.
        • Zhang J.
        • Graff A.E.
        • Grand A.P.
        • et al.
        Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in rhesus monkeys.
        Mol Psychiatry. 2007; 12: 895-897
        • Fujigaki H.
        • Saito K.
        • Fujigaki S.
        • Takemura M.
        • Sudo K.
        • Ishiguro H.
        • et al.
        The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: Involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines.
        J Biochem. 2006; 139: 655-662
        • Capuron L.
        • Neurauter G.
        • Musselman D.L.
        • Lawson D.H.
        • Nemeroff C.B.
        • Fuchs D.
        • et al.
        Interferon-alpha-induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment.
        Biol Psychiatry. 2003; 54: 906-914
        • Cai W.
        • Khaoustov V.I.
        • Xie Q.
        • Pan T.
        • Le W.
        • Yoffe B.
        Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression.
        J Hepatol. 2005; 42: 880-887
        • Dunn A.J.
        Effects of cytokines and infections on brain neurochemistry.
        Clin Neurosci Res. 2006; 6: 52-68
        • Song C.
        • Merali Z.
        • Anisman H.
        Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment.
        Neuroscience. 1999; 88: 823-836
        • Monje M.L.
        • Toda H.
        • Palmer T.D.
        Inflammatory blockade restores adult hippocampal neurogenesis.
        Science. 2003; 302: 1760-1765